Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Constantinos, Pamboukas"'
Autor:
Meletios A. Dimopoulos, Maria Roussou, Maria Gavriatopoulou, Erasmia Psimenou, Dimitrios Ziogas, Evangelos Eleutherakis-Papaiakovou, Despina Fotiou, Magdalini Migkou, Nikolaos Kanellias, Ioannis Panagiotidis, Argyrios Ntalianis, Elektra Papadopoulou, Kimon Stamatelopoulos, Efstathios Manios, Constantinos Pamboukas, Sofoklis Kontogiannis, Evangelos Terpos, Efstathios Kastritis
Publikováno v:
Blood Advances, Vol 1, Iss 7, Pp 449-454 (2017)
Abstract: Clinical trials with carfilzomib have indicated a low but reproducible incidence of cardiovascular and renal toxicities. Among 60 consecutive myeloma patients treated with carfilzomib-based regimens who were thoroughly evaluated for cardiov
Externí odkaz:
https://doaj.org/article/35f9bc8659b94494867e0d93129087e1
Autor:
Efstathios Kastritis, Athanasios Anagnostopoulos, Maria Roussou, Savvas Toumanidis, Constantinos Pamboukas, Magdalini Migkou, Anna Tassidou, Irini Xilouri, Sossana Delibasi, Erasmia Psimenou, Sofia Mellou, Evangelos Terpos, John Nanas, Meletios A. Dimopoulos
Publikováno v:
Haematologica, Vol 92, Iss 10 (2007)
Background and Objectives High-dose melphalan and autologous stem cell transplantation is currently the treatment of choice for selected patients with AL amyloidosis; however, new treatments are needed for patients who are ineligible for or relapse a
Externí odkaz:
https://doaj.org/article/e8c706f9148b4b928600d787bb15ac3b
Autor:
Ageliki Laina, Georgios Georgiopoulos, I Petropoulos, Konstantinos Stellos, Georgia Trakada, Panagiota-Efstathia Nikolaou, Ioanna Andreadou, M. Lykka, D Delialis, Evangelos Terpos, Marina Karakitsou, Kimon Stamatelopoulos, Christos Papamichael, Constantinos Pamboukas, Maria Roussou, Irene Lambrinoudaki, Efstathios Kastritis, Meletios A. Dimopoulos, Marietta Charakida, Efstathios Manios, Aikaterini Gatsiou, Maria Gavriatopoulou, Fani Athanasouli
Publikováno v:
Circulation Research
Supplemental Digital Content is available in the text.
Rationale: Cardiac involvement and hypotension dominate the prognosis of light-chain amyloidosis (AL). Evidence suggests that there is also peripheral vascular involvement in AL but its prog
Rationale: Cardiac involvement and hypotension dominate the prognosis of light-chain amyloidosis (AL). Evidence suggests that there is also peripheral vascular involvement in AL but its prog
Autor:
Nikolaos Kanellias, Magdalini Migkou, Constantinos Pamboukas, Efstathios Manios, Argyrios Ntalianis, Sofoklis Kontogiannis, Maria Gavriatopoulou, Erasmia Psimenou, Elektra Papadopoulou, Despina Fotiou, Efstathios Kastritis, Evangelos Terpos, Maria Roussou, Ioannis Panagiotidis, Dimitrios C. Ziogas, Meletios A. Dimopoulos, Evangelos Eleutherakis-Papaiakovou, Kimon Stamatelopoulos
Publikováno v:
Blood advances. 1(7)
Clinical trials with carfilzomib have indicated a low but reproducible incidence of cardiovascular and renal toxicities. Among 60 consecutive myeloma patients treated with carfilzomib-based regimens who were thoroughly evaluated for cardiovascular ri
Autor:
Constantinos Pamboukas, Sossana Delimpasi, Theofanis Apostolou, Maria Roussou, Efstathios Kastritis, Eurydiki Michalis, Meletios A. Dimopoulos, Evangelos Terpos, Nikitas Nikitas, Georgios Gkortzolidis, Smaragda Marinaki, Ioannis Boletis, Maria Gavriatopoulou
Publikováno v:
Blood. 119:5384-5390
In this phase 1/2 study, we explored the feasibility and activity of an oral regimen of lenalidomide with low-dose dexamethasone and low-dose oral cyclophosphamide (RdC) in patients with primary systemic light chain amyloidosis. RdC was given for up
Autor:
Nikolaos Zakopoulos, Constantinos Pamboukas, Eleni Koroboki, Efstathios Manios, Savvas Toumanidis, Charitini Vettou, Iliana Tsouma, F. Michas
Publikováno v:
Blood pressure monitoring. 20(3)
OBJECTIVE Ambulatory blood pressure monitoring provides a unique tool in the evaluation of night-time blood pressure (BP), having a critical role in the detection of a blunted nocturnal fall and of elevated night-time BP. Both nondipping status and n
Autor:
Michael J, Bonios, Anna, Kaladaridou, Athanasios, Tasoulis, Electra, Papadopoulou, Constantinos, Pamboukas, Argirios, Ntalianis, John, Kanakakis, John V, Terrovitis, Savvas T, Toumanidis
Publikováno v:
Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese. 55(4)
Left ventricular (LV) remodeling after acute myocardial infarction (AMI) is related to increased morbidity and mortality. The aim of the present study was to examine whether LV deformational and torsional parameters can predict LV remodeling in patie
Autor:
Constantinos Pamboukas, Savvas Toumanidis, John Agrios, Anna Kaladaridou, Elektra Papadopoulou, John Matthaiou
Publikováno v:
Echocardiography (Mount Kisco, N.Y.). 31(2)
Aims: During pregnancy, important hemodynamic changes occur, consistent with an increase inpreload and decrease in afterload and systemic vascular resistance. The aim of the present study wasto investigate the changes in left ventricular (LV) strain
Autor:
Meletios A. Dimopoulos, Maria Roussou, Maria Gavriatopoulou, Erasmia Psimenou, Dimitrios Ziogas, Evangelos Eleutherakis-Papaiakovou, Despina Fotiou, Magdalini Migkou, Nikolaos Kanellias, Ioannis Panagiotidis, Argyrios Ntalianis, Evangelos Repasos, Elektra Papadopoulou, Kimon Stamatelopoulos, Efstathios Manios, Constantinos Pamboukas, Sofoklis Kontogiannis, Evangelos Terpos, Efstathios Kastritis
Publikováno v:
Blood. 128:4491-4491
Carfilzomib (CFZ) combinations have shown activity in phase 2 and 3 studies in multiple myeloma (MM) patients but also a small but consistent signal of cardiac and renal toxicity. The aim of our study was to analyze potential cardiac and renal toxici
Autor:
Anna Tassidou, Constantinos Pamboukas, Evangelos Terpos, Efstathios Kastritis, Magdalini Migkou, Maria Roussou, Savvas Toumanidis, Athanasios Anagnostopoulos, John N. Nanas, Erasmia Psimenou, Meletios A. Dimopoulos, S. Mellou, Sossana Delibasi, Irini Xilouri
Publikováno v:
Haematologica. 92(10)
Background and Objectives High-dose melphalan and autologous stem cell transplantation is currently the treatment of choice for selected patients with AL amyloidosis; however, new treatments are needed for patients who are ineligible for or relapse a